Global Cord Blood Corporation
Global Cord Blood Corporation CO Peers
See (CO) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CO | $2.99 | N/A | 400.1M | 5.06 | $0.59 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.59% |
| TMO | $402.04 | -0.37% | 151.8B | 23.55 | $17.07 | +0.40% |
| DHR | $189.04 | -0.07% | 135.3B | 36.64 | $5.16 | +0.59% |
| IDXX | $514.33 | -0.42% | 41.4B | 47.67 | $10.79 | N/A |
| A | $110.94 | -0.29% | 31.6B | 25.44 | $4.36 | +0.87% |
| MTD | $1,155.26 | -0.65% | 24B | 28.88 | $40.00 | N/A |
| IQV | $138.66 | -1.34% | 24B | 18.89 | $7.34 | N/A |
| NTRA | $161.21 | +2.58% | 22B | -108.93 | -$1.48 | N/A |
| WAT | $354.42 | -1.10% | 21.1B | 32.10 | $11.04 | N/A |
Stock Comparison
CO vs DHR-PB Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, CO is priced at $2.99, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, CO's ROE is +0.18%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, CO is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs TMO Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, TMO has a market cap of 151.8B. Regarding current trading prices, CO is priced at $2.99, while TMO trades at $402.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas TMO's P/E ratio is 23.55. In terms of profitability, CO's ROE is +0.18%, compared to TMO's ROE of +0.13%. Regarding short-term risk, CO is more volatile compared to TMO. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs DHR Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, DHR has a market cap of 135.3B. Regarding current trading prices, CO is priced at $2.99, while DHR trades at $189.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas DHR's P/E ratio is 36.64. In terms of profitability, CO's ROE is +0.18%, compared to DHR's ROE of +0.07%. Regarding short-term risk, CO is more volatile compared to DHR. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs IDXX Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, IDXX has a market cap of 41.4B. Regarding current trading prices, CO is priced at $2.99, while IDXX trades at $514.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas IDXX's P/E ratio is 47.67. In terms of profitability, CO's ROE is +0.18%, compared to IDXX's ROE of +0.57%. Regarding short-term risk, CO is more volatile compared to IDXX. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs A Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, A has a market cap of 31.6B. Regarding current trading prices, CO is priced at $2.99, while A trades at $110.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas A's P/E ratio is 25.44. In terms of profitability, CO's ROE is +0.18%, compared to A's ROE of +0.21%. Regarding short-term risk, CO is more volatile compared to A. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs MTD Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, MTD has a market cap of 24B. Regarding current trading prices, CO is priced at $2.99, while MTD trades at $1,155.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas MTD's P/E ratio is 28.88. In terms of profitability, CO's ROE is +0.18%, compared to MTD's ROE of +1.21%. Regarding short-term risk, CO is more volatile compared to MTD. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs IQV Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, IQV has a market cap of 24B. Regarding current trading prices, CO is priced at $2.99, while IQV trades at $138.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas IQV's P/E ratio is 18.89. In terms of profitability, CO's ROE is +0.18%, compared to IQV's ROE of +0.21%. Regarding short-term risk, CO is more volatile compared to IQV. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs NTRA Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, NTRA has a market cap of 22B. Regarding current trading prices, CO is priced at $2.99, while NTRA trades at $161.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas NTRA's P/E ratio is -108.93. In terms of profitability, CO's ROE is +0.18%, compared to NTRA's ROE of -0.18%. Regarding short-term risk, CO is more volatile compared to NTRA. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs WAT Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, WAT has a market cap of 21.1B. Regarding current trading prices, CO is priced at $2.99, while WAT trades at $354.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas WAT's P/E ratio is 32.10. In terms of profitability, CO's ROE is +0.18%, compared to WAT's ROE of +0.39%. Regarding short-term risk, CO is more volatile compared to WAT. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs DGX Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, DGX has a market cap of 19.1B. Regarding current trading prices, CO is priced at $2.99, while DGX trades at $171.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas DGX's P/E ratio is 21.69. In terms of profitability, CO's ROE is +0.18%, compared to DGX's ROE of +0.13%. Regarding short-term risk, CO is more volatile compared to DGX. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs PKI Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, CO is priced at $2.99, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas PKI's P/E ratio is 41.45. In terms of profitability, CO's ROE is +0.18%, compared to PKI's ROE of +0.04%. Regarding short-term risk, CO is more volatile compared to PKI. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs ILMN Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, ILMN has a market cap of 13.4B. Regarding current trading prices, CO is priced at $2.99, while ILMN trades at $84.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas ILMN's P/E ratio is -13.89. In terms of profitability, CO's ROE is +0.18%, compared to ILMN's ROE of -0.46%. Regarding short-term risk, CO is more volatile compared to ILMN. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs EXAS Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, EXAS has a market cap of 11B. Regarding current trading prices, CO is priced at $2.99, while EXAS trades at $58.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas EXAS's P/E ratio is -10.50. In terms of profitability, CO's ROE is +0.18%, compared to EXAS's ROE of -0.36%. Regarding short-term risk, CO is more volatile compared to EXAS. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs RVTY Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, RVTY has a market cap of 10.8B. Regarding current trading prices, CO is priced at $2.99, while RVTY trades at $91.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas RVTY's P/E ratio is 36.53. In terms of profitability, CO's ROE is +0.18%, compared to RVTY's ROE of +0.04%. Regarding short-term risk, CO is more volatile compared to RVTY. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs ICLR Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, ICLR has a market cap of 10.6B. Regarding current trading prices, CO is priced at $2.99, while ICLR trades at $130.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas ICLR's P/E ratio is 14.25. In terms of profitability, CO's ROE is +0.18%, compared to ICLR's ROE of +0.08%. Regarding short-term risk, CO is more volatile compared to ICLR. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs QGEN Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, QGEN has a market cap of 9.7B. Regarding current trading prices, CO is priced at $2.99, while QGEN trades at $44.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas QGEN's P/E ratio is 103.20. In terms of profitability, CO's ROE is +0.18%, compared to QGEN's ROE of +0.03%. Regarding short-term risk, CO is more volatile compared to QGEN. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs TEM Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, TEM has a market cap of 8.9B. Regarding current trading prices, CO is priced at $2.99, while TEM trades at $53.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas TEM's P/E ratio is -10.31. In terms of profitability, CO's ROE is +0.18%, compared to TEM's ROE of -5.31%. Regarding short-term risk, CO is more volatile compared to TEM. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs MEDP Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, MEDP has a market cap of 8.4B. Regarding current trading prices, CO is priced at $2.99, while MEDP trades at $293.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas MEDP's P/E ratio is 22.44. In terms of profitability, CO's ROE is +0.18%, compared to MEDP's ROE of +0.54%. Regarding short-term risk, CO is more volatile compared to MEDP. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs CRL Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, CRL has a market cap of 6.7B. Regarding current trading prices, CO is priced at $2.99, while CRL trades at $136.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas CRL's P/E ratio is -223.43. In terms of profitability, CO's ROE is +0.18%, compared to CRL's ROE of -0.01%. Regarding short-term risk, CO is more volatile compared to CRL. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs GH Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, GH has a market cap of 4.7B. Regarding current trading prices, CO is priced at $2.99, while GH trades at $38.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas GH's P/E ratio is -11.27. In terms of profitability, CO's ROE is +0.18%, compared to GH's ROE of +3.69%. Regarding short-term risk, CO is more volatile compared to GH. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs SYNH Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, CO is priced at $2.99, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas SYNH's P/E ratio is 61.40. In terms of profitability, CO's ROE is +0.18%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, CO is more volatile compared to SYNH. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs RDNT Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, RDNT has a market cap of 4.1B. Regarding current trading prices, CO is priced at $2.99, while RDNT trades at $55.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas RDNT's P/E ratio is -128.58. In terms of profitability, CO's ROE is +0.18%, compared to RDNT's ROE of +0.03%. Regarding short-term risk, CO is more volatile compared to RDNT. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs SHC Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, SHC has a market cap of 3.5B. Regarding current trading prices, CO is priced at $2.99, while SHC trades at $12.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas SHC's P/E ratio is 135.56. In terms of profitability, CO's ROE is +0.18%, compared to SHC's ROE of +0.06%. Regarding short-term risk, CO is more volatile compared to SHC. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs OLK Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, CO is priced at $2.99, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas OLK's P/E ratio is -96.59. In terms of profitability, CO's ROE is +0.18%, compared to OLK's ROE of -0.07%. Regarding short-term risk, CO is more volatile compared to OLK. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs TWST Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, TWST has a market cap of 1.7B. Regarding current trading prices, CO is priced at $2.99, while TWST trades at $28.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas TWST's P/E ratio is -8.72. In terms of profitability, CO's ROE is +0.18%, compared to TWST's ROE of -0.41%. Regarding short-term risk, CO is more volatile compared to TWST. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs VIVO Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, VIVO has a market cap of 1.5B. Regarding current trading prices, CO is priced at $2.99, while VIVO trades at $33.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas VIVO's P/E ratio is 21.09. In terms of profitability, CO's ROE is +0.18%, compared to VIVO's ROE of +0.12%. Regarding short-term risk, CO is more volatile compared to VIVO. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs GRAL Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, GRAL has a market cap of 1.5B. Regarding current trading prices, CO is priced at $2.99, while GRAL trades at $41.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas GRAL's P/E ratio is -0.65. In terms of profitability, CO's ROE is +0.18%, compared to GRAL's ROE of -0.75%. Regarding short-term risk, CO is more volatile compared to GRAL. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs NEOG Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, NEOG has a market cap of 1.3B. Regarding current trading prices, CO is priced at $2.99, while NEOG trades at $6.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas NEOG's P/E ratio is -2.74. In terms of profitability, CO's ROE is +0.18%, compared to NEOG's ROE of -0.17%. Regarding short-term risk, CO is more volatile compared to NEOG. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs OPK Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, OPK has a market cap of 1B. Regarding current trading prices, CO is priced at $2.99, while OPK trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas OPK's P/E ratio is -21.67. In terms of profitability, CO's ROE is +0.18%, compared to OPK's ROE of -0.03%. Regarding short-term risk, CO is more volatile compared to OPK. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs CDNA Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, CDNA has a market cap of 977.7M. Regarding current trading prices, CO is priced at $2.99, while CDNA trades at $17.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas CDNA's P/E ratio is 15.68. In terms of profitability, CO's ROE is +0.18%, compared to CDNA's ROE of +0.18%. Regarding short-term risk, CO is more volatile compared to CDNA. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs FLGT Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, FLGT has a market cap of 625.6M. Regarding current trading prices, CO is priced at $2.99, while FLGT trades at $20.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas FLGT's P/E ratio is -15.45. In terms of profitability, CO's ROE is +0.18%, compared to FLGT's ROE of -0.04%. Regarding short-term risk, CO is more volatile compared to FLGT. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs GRALV Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, CO is priced at $2.99, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas GRALV's P/E ratio is N/A. In terms of profitability, CO's ROE is +0.18%, compared to GRALV's ROE of N/A. Regarding short-term risk, CO is more volatile compared to GRALV. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs CSTL Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, CSTL has a market cap of 468.6M. Regarding current trading prices, CO is priced at $2.99, while CSTL trades at $16.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas CSTL's P/E ratio is -85.42. In terms of profitability, CO's ROE is +0.18%, compared to CSTL's ROE of -0.01%. Regarding short-term risk, CO is more volatile compared to CSTL. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs PSNL Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, PSNL has a market cap of 416.1M. Regarding current trading prices, CO is priced at $2.99, while PSNL trades at $4.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas PSNL's P/E ratio is -3.65. In terms of profitability, CO's ROE is +0.18%, compared to PSNL's ROE of -0.49%. Regarding short-term risk, CO is more volatile compared to PSNL. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs LAB Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, LAB has a market cap of 414M. Regarding current trading prices, CO is priced at $2.99, while LAB trades at $1.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas LAB's P/E ratio is -3.41. In terms of profitability, CO's ROE is +0.18%, compared to LAB's ROE of -0.28%. Regarding short-term risk, CO is more volatile compared to LAB. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs MYGN Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, MYGN has a market cap of 398.2M. Regarding current trading prices, CO is priced at $2.99, while MYGN trades at $4.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas MYGN's P/E ratio is -3.86. In terms of profitability, CO's ROE is +0.18%, compared to MYGN's ROE of -0.15%. Regarding short-term risk, CO is more volatile compared to MYGN. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs FLDM Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, CO is priced at $2.99, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas FLDM's P/E ratio is -4.74. In terms of profitability, CO's ROE is +0.18%, compared to FLDM's ROE of -0.28%. Regarding short-term risk, CO is more volatile compared to FLDM. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs STIM Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, STIM has a market cap of 253.4M. Regarding current trading prices, CO is priced at $2.99, while STIM trades at $3.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas STIM's P/E ratio is -2.92. In terms of profitability, CO's ROE is +0.18%, compared to STIM's ROE of -2.09%. Regarding short-term risk, CO is more volatile compared to STIM. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs NEO Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, NEO has a market cap of 191M. Regarding current trading prices, CO is priced at $2.99, while NEO trades at $7.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas NEO's P/E ratio is -11.97. In terms of profitability, CO's ROE is +0.18%, compared to NEO's ROE of -0.09%. Regarding short-term risk, CO is more volatile compared to NEO. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs ACRS Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, ACRS has a market cap of 152.7M. Regarding current trading prices, CO is priced at $2.99, while ACRS trades at $1.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas ACRS's P/E ratio is -0.89. In terms of profitability, CO's ROE is +0.18%, compared to ACRS's ROE of -0.92%. Regarding short-term risk, CO is more volatile compared to ACRS. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs XGN Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, XGN has a market cap of 146.4M. Regarding current trading prices, CO is priced at $2.99, while XGN trades at $6.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas XGN's P/E ratio is -7.98. In terms of profitability, CO's ROE is +0.18%, compared to XGN's ROE of -1.34%. Regarding short-term risk, CO is more volatile compared to XGN. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs PRENW Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, PRENW has a market cap of 140.1M. Regarding current trading prices, CO is priced at $2.99, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas PRENW's P/E ratio is N/A. In terms of profitability, CO's ROE is +0.18%, compared to PRENW's ROE of -0.25%. Regarding short-term risk, CO is more volatile compared to PRENW. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs PRE Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, PRE has a market cap of 131M. Regarding current trading prices, CO is priced at $2.99, while PRE trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas PRE's P/E ratio is -2.71. In terms of profitability, CO's ROE is +0.18%, compared to PRE's ROE of -0.25%. Regarding short-term risk, CO is more volatile compared to PRE. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs GTH Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, CO is priced at $2.99, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas GTH's P/E ratio is -1.11. In terms of profitability, CO's ROE is +0.18%, compared to GTH's ROE of +0.00%. Regarding short-term risk, CO is more volatile compared to GTH. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs GENE Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, CO is priced at $2.99, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas GENE's P/E ratio is -38.25. In terms of profitability, CO's ROE is +0.18%, compared to GENE's ROE of -3.62%. Regarding short-term risk, CO is more volatile compared to GENE. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs MDXH Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, MDXH has a market cap of 104.2M. Regarding current trading prices, CO is priced at $2.99, while MDXH trades at $2.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas MDXH's P/E ratio is -2.02. In terms of profitability, CO's ROE is +0.18%, compared to MDXH's ROE of -6.91%. Regarding short-term risk, CO is more volatile compared to MDXH. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs NOTV Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, NOTV has a market cap of 83.5M. Regarding current trading prices, CO is priced at $2.99, while NOTV trades at $2.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas NOTV's P/E ratio is -0.78. In terms of profitability, CO's ROE is +0.18%, compared to NOTV's ROE of -0.51%. Regarding short-term risk, CO is more volatile compared to NOTV. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs SERA Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, SERA has a market cap of 60.6M. Regarding current trading prices, CO is priced at $2.99, while SERA trades at $1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas SERA's P/E ratio is -1.76. In terms of profitability, CO's ROE is +0.18%, compared to SERA's ROE of -0.51%. Regarding short-term risk, CO is more volatile compared to SERA. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs VNRX Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, VNRX has a market cap of 51.5M. Regarding current trading prices, CO is priced at $2.99, while VNRX trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas VNRX's P/E ratio is -1.85. In terms of profitability, CO's ROE is +0.18%, compared to VNRX's ROE of +1.08%. Regarding short-term risk, CO is more volatile compared to VNRX. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs BDSX Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, BDSX has a market cap of 50.3M. Regarding current trading prices, CO is priced at $2.99, while BDSX trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas BDSX's P/E ratio is -1.27. In terms of profitability, CO's ROE is +0.18%, compared to BDSX's ROE of -1.68%. Regarding short-term risk, CO is more volatile compared to BDSX. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs OPGN Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, OPGN has a market cap of 47.3M. Regarding current trading prices, CO is priced at $2.99, while OPGN trades at $4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas OPGN's P/E ratio is -0.30. In terms of profitability, CO's ROE is +0.18%, compared to OPGN's ROE of +1.20%. Regarding short-term risk, CO is more volatile compared to OPGN. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs DRIO Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, DRIO has a market cap of 30.9M. Regarding current trading prices, CO is priced at $2.99, while DRIO trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas DRIO's P/E ratio is -1.26. In terms of profitability, CO's ROE is +0.18%, compared to DRIO's ROE of -0.17%. Regarding short-term risk, CO is more volatile compared to DRIO. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs STRRP Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, STRRP has a market cap of 29.7M. Regarding current trading prices, CO is priced at $2.99, while STRRP trades at $9.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas STRRP's P/E ratio is -4.63. In terms of profitability, CO's ROE is +0.18%, compared to STRRP's ROE of -0.24%. Regarding short-term risk, CO is more volatile compared to STRRP. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs AKU Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, CO is priced at $2.99, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas AKU's P/E ratio is -0.13. In terms of profitability, CO's ROE is +0.18%, compared to AKU's ROE of -5.32%. Regarding short-term risk, CO is more volatile compared to AKU. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs ADVB Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, ADVB has a market cap of 25.3M. Regarding current trading prices, CO is priced at $2.99, while ADVB trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas ADVB's P/E ratio is -7.31. In terms of profitability, CO's ROE is +0.18%, compared to ADVB's ROE of -1.86%. Regarding short-term risk, CO is more volatile compared to ADVB. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs CEMI Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, CO is priced at $2.99, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas CEMI's P/E ratio is -0.63. In terms of profitability, CO's ROE is +0.18%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, CO is more volatile compared to CEMI. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs ENZ Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, CO is priced at $2.99, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas ENZ's P/E ratio is -2.24. In terms of profitability, CO's ROE is +0.18%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, CO is more volatile compared to ENZ. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs PMD Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, PMD has a market cap of 15.7M. Regarding current trading prices, CO is priced at $2.99, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas PMD's P/E ratio is -5.24. In terms of profitability, CO's ROE is +0.18%, compared to PMD's ROE of -0.33%. Regarding short-term risk, CO is more volatile compared to PMD. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs PRPO Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, PRPO has a market cap of 15.1M. Regarding current trading prices, CO is priced at $2.99, while PRPO trades at $9.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas PRPO's P/E ratio is -4.83. In terms of profitability, CO's ROE is +0.18%, compared to PRPO's ROE of -0.26%. Regarding short-term risk, CO is more volatile compared to PRPO. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs ME Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, ME has a market cap of 13.3M. Regarding current trading prices, CO is priced at $2.99, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas ME's P/E ratio is -0.03. In terms of profitability, CO's ROE is +0.18%, compared to ME's ROE of -3.10%. Regarding short-term risk, CO is more volatile compared to ME. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs BNGO Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, BNGO has a market cap of 12.4M. Regarding current trading prices, CO is priced at $2.99, while BNGO trades at $3.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas BNGO's P/E ratio is -0.07. In terms of profitability, CO's ROE is +0.18%, compared to BNGO's ROE of -1.57%. Regarding short-term risk, CO is more volatile compared to BNGO. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs BIAFW Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, BIAFW has a market cap of 10.9M. Regarding current trading prices, CO is priced at $2.99, while BIAFW trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas BIAFW's P/E ratio is N/A. In terms of profitability, CO's ROE is +0.18%, compared to BIAFW's ROE of -3.68%. Regarding short-term risk, CO is more volatile compared to BIAFW. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs BIAF Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, BIAF has a market cap of 10.9M. Regarding current trading prices, CO is priced at $2.99, while BIAF trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas BIAF's P/E ratio is -0.56. In terms of profitability, CO's ROE is +0.18%, compared to BIAF's ROE of -3.68%. Regarding short-term risk, CO is less volatile compared to BIAF. This indicates potentially lower risk in terms of short-term price fluctuations for CO.
CO vs INBS Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, INBS has a market cap of 10M. Regarding current trading prices, CO is priced at $2.99, while INBS trades at $1.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas INBS's P/E ratio is -1.09. In terms of profitability, CO's ROE is +0.18%, compared to INBS's ROE of -1.72%. Regarding short-term risk, CO is more volatile compared to INBS. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs CNTG Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, CO is priced at $2.99, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas CNTG's P/E ratio is -0.23. In terms of profitability, CO's ROE is +0.18%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, CO is more volatile compared to CNTG. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs MYNZ Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, MYNZ has a market cap of 7.6M. Regarding current trading prices, CO is priced at $2.99, while MYNZ trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas MYNZ's P/E ratio is -0.09. In terms of profitability, CO's ROE is +0.18%, compared to MYNZ's ROE of -22.70%. Regarding short-term risk, CO is more volatile compared to MYNZ. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs STRR Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, STRR has a market cap of 6.7M. Regarding current trading prices, CO is priced at $2.99, while STRR trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas STRR's P/E ratio is -0.70. In terms of profitability, CO's ROE is +0.18%, compared to STRR's ROE of -0.24%. Regarding short-term risk, CO is more volatile compared to STRR. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs BGLC Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, BGLC has a market cap of 5.7M. Regarding current trading prices, CO is priced at $2.99, while BGLC trades at $3.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas BGLC's P/E ratio is -2.65. In terms of profitability, CO's ROE is +0.18%, compared to BGLC's ROE of -0.24%. Regarding short-term risk, CO is more volatile compared to BGLC. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs NVTA Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, CO is priced at $2.99, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas NVTA's P/E ratio is -0.00. In terms of profitability, CO's ROE is +0.18%, compared to NVTA's ROE of +1.79%. Regarding short-term risk, CO is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for CO.
CO vs LMDXW Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, CO is priced at $2.99, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, CO's ROE is +0.18%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, CO is more volatile compared to LMDXW. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs LMDX Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, CO is priced at $2.99, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas LMDX's P/E ratio is -0.01. In terms of profitability, CO's ROE is +0.18%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, CO is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for CO.
CO vs CHEK Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, CHEK has a market cap of 4.9M. Regarding current trading prices, CO is priced at $2.99, while CHEK trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas CHEK's P/E ratio is -0.39. In terms of profitability, CO's ROE is +0.18%, compared to CHEK's ROE of -0.52%. Regarding short-term risk, CO is more volatile compared to CHEK. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs TTOO Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, TTOO has a market cap of 4.6M. Regarding current trading prices, CO is priced at $2.99, while TTOO trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas TTOO's P/E ratio is -5.50. In terms of profitability, CO's ROE is +0.18%, compared to TTOO's ROE of +2.06%. Regarding short-term risk, CO is more volatile compared to TTOO. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs APDN Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, APDN has a market cap of 3.4M. Regarding current trading prices, CO is priced at $2.99, while APDN trades at $0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas APDN's P/E ratio is N/A. In terms of profitability, CO's ROE is +0.18%, compared to APDN's ROE of -2.81%. Regarding short-term risk, CO is more volatile compared to APDN. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs BNR Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, BNR has a market cap of 3.3M. Regarding current trading prices, CO is priced at $2.99, while BNR trades at $3.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas BNR's P/E ratio is -0.65. In terms of profitability, CO's ROE is +0.18%, compared to BNR's ROE of -0.53%. Regarding short-term risk, CO is more volatile compared to BNR. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs DMTK Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, CO is priced at $2.99, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas DMTK's P/E ratio is -0.04. In terms of profitability, CO's ROE is +0.18%, compared to DMTK's ROE of -1.39%. Regarding short-term risk, CO is more volatile compared to DMTK. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs AWH Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, AWH has a market cap of 2.9M. Regarding current trading prices, CO is priced at $2.99, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas AWH's P/E ratio is -0.09. In terms of profitability, CO's ROE is +0.18%, compared to AWH's ROE of +4.66%. Regarding short-term risk, CO is more volatile compared to AWH. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs ISPC Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, ISPC has a market cap of 2.7M. Regarding current trading prices, CO is priced at $2.99, while ISPC trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas ISPC's P/E ratio is -0.09. In terms of profitability, CO's ROE is +0.18%, compared to ISPC's ROE of -2.39%. Regarding short-term risk, CO is more volatile compared to ISPC. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs SQL Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, CO is priced at $2.99, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas SQL's P/E ratio is -0.40. In terms of profitability, CO's ROE is +0.18%, compared to SQL's ROE of +10.89%. Regarding short-term risk, CO is more volatile compared to SQL. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs NDRA Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, NDRA has a market cap of 2.4M. Regarding current trading prices, CO is priced at $2.99, while NDRA trades at $3.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas NDRA's P/E ratio is 0.01. In terms of profitability, CO's ROE is +0.18%, compared to NDRA's ROE of -1.96%. Regarding short-term risk, CO is more volatile compared to NDRA. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs HTGM Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, CO is priced at $2.99, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas HTGM's P/E ratio is -0.03. In terms of profitability, CO's ROE is +0.18%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, CO is more volatile compared to HTGM. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs SQLLW Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, SQLLW has a market cap of 871.8K. Regarding current trading prices, CO is priced at $2.99, while SQLLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas SQLLW's P/E ratio is -0.04. In terms of profitability, CO's ROE is +0.18%, compared to SQLLW's ROE of -19.68%. Regarding short-term risk, CO is more volatile compared to SQLLW. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs TRIB Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, TRIB has a market cap of 589.3K. Regarding current trading prices, CO is priced at $2.99, while TRIB trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas TRIB's P/E ratio is -0.35. In terms of profitability, CO's ROE is +0.18%, compared to TRIB's ROE of +0.79%. Regarding short-term risk, CO is more volatile compared to TRIB. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs BIOC Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, CO is priced at $2.99, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas BIOC's P/E ratio is -0.01. In terms of profitability, CO's ROE is +0.18%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, CO is more volatile compared to BIOC. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs MEUSW Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, CO is priced at $2.99, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas MEUSW's P/E ratio is N/A. In terms of profitability, CO's ROE is +0.18%, compared to MEUSW's ROE of -3.10%. Regarding short-term risk, CO is more volatile compared to MEUSW. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs OCDX Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, CO is priced at $2.99, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas OCDX's P/E ratio is -42.28. In terms of profitability, CO's ROE is +0.18%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, CO is more volatile compared to OCDX. This indicates potentially higher risk in terms of short-term price fluctuations for CO.
CO vs DHR-PA Comparison
CO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CO stands at 400.1M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, CO is priced at $2.99, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CO currently has a P/E ratio of 5.06, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, CO's ROE is +0.18%, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, CO is more volatile compared to DHR-PA. This indicates potentially higher risk in terms of short-term price fluctuations for CO.